ReviewCancers2022

Controversies and Opportunities in the Clinical Daily Use of the 21-Gene Assay for Prognostication and Prediction of Chemotherapy Benefit in HR+/HER2- Early Breast Cancer.

Flavia Jacobs et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.